Home
|
Job-opportunities
|
Contact
|
News
|
Donate
Search
About Us
|
Overview
DNDi Worldwide
Business Model
Our People
Friends of DNDi
Annual Report
DNDi's Policies
Letter from Chairman and Executive Director
|
Diseases & Projects
|
Diseases
Portfolio
R&D Organisation
Building Portfolio
Clinical Trial Protocols
Open Innovation
|
Treatments
|
Overview
ASAQ (Malaria)
ASMQ (Malaria)
NECT (HAT)
SSG&PM (VL)
Paediatric Benznidazole
New VL treatments in Asia
|
Strengthening Capacity
|
Overview
LEAP Platform
HAT Platform
Chagas Platform
Technology Transfer ASMQ
Technology Transfer ASAQ
|
Advocacy
|
Global
Access
IP
Regulatory
Voices for Neglected Diseases
DNDi Viewpoint
Sustainable Funding
|
Media Centre
|
Overview
Press Room
Press Kit
Annual Report
Press Releases
Press Articles
Scientific Publications
Newsletters
Outlooks
Multimedia
Events
|
Partnership
|
Overview
Business Model
Partners
IP & Licensing Policies
To Become a DNDi Partner
|
Donors
|
Overview
How to help
Donors
Key Financial Figures
Fundraising Policy
Donate
Diseases & Projects
/
Portfolio
Diseases
Portfolio
Topical Amp B (CL)
Anfoleish (CL)
Nitroimidazole (Chagas)
Fexinidazole (VL)
PI sprinkles (CHAPAS-2)
“Superboosting” - TB/HIV
Screening & Lead optimisation
Nitroimidazole backup (HAT)
Oxaborole backup (HAT)
VL-2098
Alt. formulations Amphotericin B
Nitroimidazole backup (VL)
Fenarimol series
K777
Flubendazole Macrofilaricide (Helminth)
Improved PI for 1st-line
Fexinidazole (HAT)
Oxaborole SCYX-7158
New VL treatments (Bangladesh)
New VL treatments (Africa)
New VL treatments (Latin America)
HIV/VL
Azoles E1224 & Biomarker (Chagas)
ASAQ
ASMQ
NECT
SSG&PM co-administration
New VL treatments (Asia)
Benznidazole Paedriatric dosage form
R&D Phases
R&D Organisation
Building Portfolio
Clinical Trial Protocols
Open Innovation
DNDi R&D Projects - 2013 Outlook
Discovery
HAT
Screening & Lead Optimisation
Leishmaniasis
Chagas
Helminths
Paediatric HIV
Malaria
Pre-clinical
Nitroimidazole backup (HAT)
Oxaborole backup (HAT)
VL-2098 (VL)
Nitroimidazole backup (VL)
Nitroimidazole (Chagas)
Fenarimol series (Chagas)
K777 (Chagas)
Flubendazole - Macrofilaricide (Helminth)
Improved PI for 1st-line
Clinical
Fexinidazole Phase 2/3
Oxaborole SCYX-7158 (HAT)
Fexinidazole (VL)
Anfoleish (CL)
New VL treatments - Bangladesh
New VL treatments - Africa · AmBisome© · Miltefosine
New VL treatments - (Latin America)
HIV / VL
Azoles E1224 & Biomarker (Chagas)
PI sprinkles (CHAPAS-2)
"Superboosting" - TB/HIV
Implementation
NECT (Stage 2 HAT)
Nifurtimox - Eflornithine
Co-administration
SSG&PM
Co-administration
VL in Africa
New VL treatments in Asia
(SD AmBisome®, 3 drug combinations)
Benznidazole Paed. dosage form
(Chagas)
ASAQ
Fixed-Dose
Artesunate/Amodiaquine
ASMQ
Fixed-Dose
Artesunate/Mefloquine
Chagas: Chagas disease
HAT: human African trypanosomiasis
VL: visceral leishmaniasis
CL: cutaneous leishmaniasis
See
DNDi Portfolio Map 2011
[PDF]
Tweet
SITEMAP
DISCLAIMER
PRIVACY
Except where otherwise noted, content on this site is licensed under a Creative Commons Attribution-Noncommercial-Share Alike 2.5 Switzerland License